<DOC>
	<DOCNO>NCT00192452</DOCNO>
	<brief_summary>- The primary objective study compare disease activity , measure PASI score , two MEDI-507 dose level ( 0.012 0.04 mg/kg ) versus placebo administer intravenous infusion every 2 week total 8 infusion .</brief_summary>
	<brief_title>Study MEDI-507 Administered Intravenous Infusion Adults With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Plaque psoriasis involve least 10 % body surface area ( Appendix B ) Age 18 65 year time first dose study drug Both males female eligible . However , sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose study drug must agree continue use precaution 60 day final dose study drug Currently receive therapy psoriasis except emollient ( certain overthecounter product may allow prior approval sponsor ) Written informed consent obtain patient Ability complete followup period 188 day require protocol Pustular , guttate , erythrodermic psoriasis predominant disease type PASI score &lt; 8 At screening ( must within 21 day study entry ) following : lymphocyte count 1,200 cells/mm3 , WBC 4,000 cells/mm3 , hematocrit 32 % , platelets 110,000 cells/mm3 , creatinine , AST , ALT 1.5 time upper limit normal At screen ( must within 21 day study entry ) clinical evidence HIV , hepatitis B , hepatitis C active hepatitis A infection Pregnancy ( must negative serum pregnancy test within 21 day prior first dose study drug , urine pregnancy test must negative Study Day 0 study entry ) History cancer ( except excision basal cell carcinoma ) Any document immunodeficiency A history prior administration monoclonal antibody related protein , exception MEDI507 ( Note : prior recipient MEDI507 require review approval sponsor prior entry ) Receipt systemic retinoids , corticosteroid , cyclosporin A , methotrexate , phototherapy coal tar treatment past 4 week Use topical therapy ( except emollient ) psoriasis past 2 week ( certain overthecounter product may allow prior approval sponsor ) Receipt investigational drug therapy within 6 week first dose study drug protocol ( use license agent indication list package insert permit ) Current plan participation research protocol investigational agent therapy may administer Nursing mother Acute illness include infection Clinical manifestation significant end organ dysfunction failure may compromise safety volunteer study A known drug allergy medical contraindication ibuprofen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>